HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Villarejos M., V. M. Search for Related Content PubMed Articles by Villarejos M., V. M.

Experiences with Amodiaquin (Camoquin¹⁾ A New Synthetic Antimalarial

At the beginning of 1948 a supply of a new synthetic antimalarial became available. This drug, amodiaquin (Camoquin Hydrochloride) is 4(3'-diethylamino-methyl-4'-hydroxyanilino)-7-chloroquinoline dihydrochloride dihydrate. It is a light yellow, crystalline powder which forms a 5 per cent solution in water at room temperature. It was first reported at the meeting of the American Chemical Society by Burckhalter et al. (1) in 1946. Its toxicity and tolerance have been determined by the parent laboratory, and it has been studied clinically (2, 3, 4, 5, 6, 7, 8, 9, 10) in numerous countries.

La Paz, Bolivia, where this study was conducted offers a fortunate combination of circumstances for a therapeutic evaluation of an antimalarial. Due to the cool climate and the altitude no vectors of the disease exist, thus there is no danger of reinfections contaminating the resulting follow-up observation. Second, the altitude increases the tendency of a dormant case of malaria to relapse.

¹ Camoquin is Parke, Davis and Company's registered trademark for amodiaquin. (Note: Camoquin used in this study was furnished by Department of Clinical Investigation, Parke, Davis and Company.)

² Professor of Tropical Pathology, University of San Andrés, La Paz, Bolivia.